Myriad Genetics has entered into a strategic partnership with PATHOMIQ, securing exclusive U.S. licensing rights for PATHOMIQ_PRAD, an artificial intelligence platform designed for prostate cancer prognosis. This collaboration aims to enhance treatment decision-making capabilities for healthcare providers managing prostate cancer patients.
The AI-powered platform analyzes complex morphological structures in cancer pathology, providing crucial insights for treatment planning at various stages - from initial biopsy through post-surgical or post-radiation therapy care. A key advantage of the system is its rapid turnaround time, delivering results within 1-2 days after receiving patient sample digital images.
Clinical Validation Shows Promising Results
Research published in European Urology has validated PATHOMIQ_PRAD's effectiveness in risk stratifying prostate cancer progression. The study, conducted at the Icahn School of Medicine at Mount Sinai, examined 176 patients with intermediate-risk prostate cancer who underwent radical prostatectomy.
The results were compelling: PATHOMIQ_PRAD successfully identified high-risk patients for biochemical recurrence (HR, 4.347; P <.0001) and metastasis (HR, 4.656; P <.0005). Notably, the platform demonstrated superior net benefit compared to established tools like CAPRA-S and traditional genomic scores in predicting both 3-year and 5-year likelihood of biochemical recurrence and 5-year probability of metastasis.
Expert Perspectives on Clinical Impact
Dr. Ash Tewari, Chair of Urology at Mount Sinai, who co-developed the AI model, emphasized its significance: "The AI model has achieved high prediction accuracy and outperformed some of the currently used markers in both Caucasian and African American patient cohorts for a much-improved patient outcome."
Dr. Sujit S. Nair, Director of GU Immunotherapy Research at Mount Sinai, highlighted the platform's broader implications: "PATHOMIQ_PRAD demonstrates superior clinical utility in predicting risk... and could potentially impact patient management, personalized therapy, biomarker discovery, and patient selection for clinical trials of novel therapies."
Integration with Existing Diagnostic Tools
This partnership complements Myriad's existing diagnostic portfolio, including their Prolaris test, which recently received recognition as an "Advanced Tool" in prostate cancer treatment. According to NCCN guidelines, such advanced tools demonstrate superior prognostic performance compared to standard tools and help identify patients who may benefit from specific therapies.
The integration of PATHOMIQ_PRAD into clinical practice represents a significant advancement in precision medicine for prostate cancer, offering healthcare providers more sophisticated tools for treatment planning and patient risk stratification.
